AzTrials
AzTrials

Rheumatoid ArthritisPhase 4NCT02831855

Methotrexate Withdrawal Study of Tofacitinib Modified Release Formulation in Subjects With Rheumatoid Arthritis

A Phase 4 study testing CP-690,550 and Methotrexate in people with Rheumatoid Arthritis, run by Pfizer at 136 sites in 16 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study is designed to evaluate the efficacy and safety of tofacitinib modified release formulation (11mg QD) versus tofacitinib modified release formulation plus continued methotrexate treatment in subjects with moderate to severe rheumatoid arthritis who are insufficiently responding to their stable dose of… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Rheumatoid Arthritis
What is being tested?
CP-690,550 and Methotrexate
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
694 participants
Where
136 sitesin 16 countries
Study dates
1 Sep 2016to 17 Dec 2018
Phase
Phase 4
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Must be 18 years of age or older.
  • Have a score of 6 or greater on the 2010 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Rheumatoid Arthritis at and/or prior to Screening Visit.
  • Have ≥4 tender/painful joints on motion and ≥4 swollen joints (28 joint counts) at both Screening Visit and Baseline Visit (Visit 1).
  • Have moderate to severe disease activity as defined by CDAI>10 and DAS28-4(ESR) ≥3.2 at Baseline Visit.
  • Have taken an oral MTX treatment regimen (15-25mg/week) continuously for at least 4 months prior to the screening visit and has taken a stable weekly dose of oral MTX with supplemental folic acid or folinic acid for at least 4 weeks prior to the baseline visit (conversion from parenteral MTX to oral MTX will require stabilization of the treatment regimen for at least 1 month).
  • Subjects must screen negative for active tuberculosis or inadequately treated tuberculosis infection (active or latent).

Who cannot join

  • Pregnant female subjects; breastfeeding female subjects; male subjects with partners currently pregnant; male subjects able to father children and female subjects of childbearing potential who are unwilling or unable to use 2 highly effective methods of contraception as outlined in this protocol for the duration of the study and for at least 3 months after the last dose of investigational product.
  • Subjects with infection or infection history; subjects with any current malignancy or a history of malignancy (except adequately treated or excised non-metastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in situ); subjects with history of, or current evidence for, severe gastrointestinal narrowing (pathologic or iatrogenic); and subjects with history of documented diverticulitis.
  • Subjects with a history of insufficient response to ≥2 biologics, regardless of the class.

Trial locations and contacts

136 sites in 16 countries.

136 sites in 16 countries

United States59 sites
  • AARDS Research Inc

    Aventura, Florida, 33180

  • Ochsner Clinic Baton Rouge

    Baton Rouge, Louisiana, 70836

  • Bronson Internal Medicine and Rheumatology

    Battle Creek, Michigan, 49015

  • East Penn Rheumatology Associates, P.C.

    Bethlehem, Pennsylvania, 18015

  • RASF-Clinical Research Inc

    Boca Raton, Florida, 33486

  • Center for Arthritis and Rheumatic Diseases

    Chesapeake, Virginia, 23320

  • Group Health Associates

    Cincinnati, Ohio, 45236

  • Cincinnati Rheumatic Disease Study Group, Inc.

    Cincinnati, Ohio, 45242

  • Pioneer Research Solutions, Inc.

    Cypress, Texas, 77429

  • Metroplex Clinical Research Center

    Dallas, Texas, 75231

  • STAT Research, Inc.

    Dayton, Ohio, 45417

  • Omega Research Consultants

    DeBary, Florida, 32713

  • Altoona Center for Clinical Research

    Duncansville, Pennsylvania, 16635

  • Med Investigations, Inc

    Fair Oaks, California, 95628

  • Phase III Clinical Research

    Fall River, Massachusetts, 02720

  • Arthritis & Osteoporosis Associates

    Freehold, New Jersey, 07728

  • Arthrocare, Arthritiscare & Research, PC

    Gilbert, Arizona, 85234

  • Beacon Medical Group Rheumatology Main Street

    Granger, Indiana, 46530

  • Physicians East, PA

    Greenville, North Carolina, 27834

  • Piedmont Arthritis Clinic

    Greenville, South Carolina, 29601

  • CHI St. Vincent Medical Group Hot Springs

    Hot Springs, Arkansas, 71913

  • HCP Clinical Research, LLC

    Huntington Beach, California, 92646

  • Rheumatology Associates of North Alabama, PC

    Huntsville, Alabama, 35801-4418

  • Institute of Arthritis Research

    Idaho Falls, Idaho, 83404

  • Diagnostic Rheumatology and Research, PC

    Indianapolis, Indiana, 46227

  • University of Florida College of Medicine - Jacksonville - Rheumatology Research

    Jacksonville, Florida, 32207

  • University of Florida, Rheumatology at ACC

    Jacksonville, Florida, 32209

  • Western Michigan University Homer Stryker MD

    Kalamazoo, Michigan, 49007

  • Radnet

    Marlton, New Jersey, 08053

  • Center for Arthritis and Rheumatic Diseases

    Miami, Florida, 33173

  • Trinity Health Center-Medical Arts

    Minot, North Dakota, 58701

  • Jeffrey Alper, MD

    Naples, Florida, 34102

  • Medallion Clinical Research Institute, LLC

    Naples, Florida, 34102

  • Suncoast Clinical Research, Inc.

    New Port Richey, Florida, 34652

  • Health Research of Oklahoma

    Oklahoma City, Oklahoma, 73103

  • Oklahoma Medical Research Foundation (OMRF)

    Oklahoma City, Oklahoma, 73104

  • Lynn Health Science Institute

    Oklahoma City, Oklahoma, 73112

  • Articularis Healthcare Group dba ACME Research

    Orangeburg, South Carolina, 29118

  • SunValley Arthritis Center, Ltd.

    Peoria, Arizona, 85381

  • Florida Arthritis & Osteoporosis Center

    Port Richey, Florida, 34668

  • Gulf Coast Medical Center

    Port Richey, Florida, 34668

  • Quincy Medical Group

    Quincy, Illinois, 62301

  • AAIR Research Center

    Rochester, New York, 14618

  • Sierra Rheumatology

    Roseville, California, 95661

  • PMG Research of Salisbury

    Salisbury, North Carolina, 28144

  • Pacific Arthritis Center Medical Group

    Santa Maria, California, 93454

  • Center for Arthritis and Rheumatic Diseases

    Suffolk, Virginia, 23435

  • Articularis Healthcare Group d/b/a Low Country Rheumatology

    Summerville, South Carolina, 29486

  • West Broward Rheumatology Associates, Inc.

    Tamarac, Florida, 33321

  • USF Health Morsani Center for Advanced Healthcare

    Tampa, Florida, 33612

  • BayCare Medical Group, Inc

    Tampa, Florida, 33614

  • North Mississippi Medical Clinics, Inc. - Clinical Research

    Tupelo, Mississippi, 38801

  • Robin K. Dore, MD, Inc.

    Tustin, California, 92780

  • Inland Rheumatology and Osteoporosis Medical Group

    Upland, California, 91786

  • Inland Rheumatology Clinical Trials, Inc.

    Upland, California, 91786

  • Desert Valley Medical Group

    Victorville, California, 92395

  • Arthritis, Rheumatic & Back Disease Associates, P.A.

    Voorhees Township, New Jersey, 08043

  • Open MRI & Diagnostic Imaging of Wall

    Wall, New Jersey, 07719

  • Clinical Pharmacology Study Group

    Worcester, Massachusetts, 01605

Other trials in United States

Czechia12 sites
  • CCBR Czech Brno, s.r.o.

    Brno, Czech Republic, 602 00

  • LEKARNA LANCIER s.r.o.

    Brno, 602 00

  • Lekarna Na Lidicke

    Brno, 602 00

  • Revmacentrum MUDr. Mostera, s.r.o., Revmatologie a interna

    Brno, 615 00

  • CCBR Ostrava, s.r.o.

    Ostrava, 702 00

  • Lekarna Rezidence Nova Karolina

    Ostrava, 702 00

  • Revmatologicky ustav, Lekrna

    Prague, 128 50

  • Revmatologicky ustav

    Prague, 128 50

  • Lekarna Hradebni s.r.o.

    Uherské Hradiště, 686 01

  • MEDICAL PLUS, s.r.o. Revmatologicka a osteologicka ambulance

    Uherské Hradiště, 686 01

  • PV - MEDICAL s.r.o., Revmatologicka ambulance

    Zlín, 760 01

  • Revmavita s.r.o, Lekarna

    Zlín, 760 01

Other trials in Czechia

United Kingdom12 sites
  • Hampshire Hospitals NHS Foundation Trust

    Basingstoke, Hampshire, RG24 9NA

  • Pharmacy, Hampshire Hospitals NHS Foundation Trust

    Basingstoke, Hampshire, RG24 9NA

  • Countess of Chester Hospital NHS Foundation Trust

    Chester, Cheshire, CH2 1UL

  • Pharmacy (dispensary)

    Chester, Cheshire, CH2 1UL

  • Pharmacy Department

    Dudley, WEST Midlands, DY1 2HQ

  • The Dudley Group NHS Foundation Trust

    Dudley, WEST Midlands, DY1 2HQ

  • Countess of Chester Hospital NHS Foundation Trust

    Ellesmere Port, Cheshire, CH65 6SG

  • Pharmacy

    Manchester, M23 9LT

  • University Hospital of South Manchester NHS Foundation Trust

    Manchester, M23 9LT

  • Department of Rheumatology, Wirral University Teaching Hospital NHS Foundation Trust

    Metropolitan Borough of Wirral, Merseyside, CH49 5PE

  • Pharmacy Department, Wirral University Teaching Hospital NHS Foundation Trust

    Metropolitan Borough of Wirral, Merseyside, CH49 5PE

  • Wirral University Teaching Hospital NHS Foundation Trust

    Metropolitan Borough of Wirral, Merseyside, CH49 5PE

Other trials in United Kingdom

Russia9 sites
  • Federal State Budgetary Scientific Institution "Research Institute of Rheumatology

    Moscow, 115522

  • FSBEI HE "Orenburg State Medical University" of MoH RF

    Orenburg, 460000

  • FSBEI HE "Orenburg State Medical University" of MoH RF

    Orenburg, 460018

  • FSBIH "Clinical Hospital #122 n.a. L.G. Sokolov" of FMBA of Russia

    Saint Petersburg, 194291

  • SPb SBIH "Consultative-Diagnostic Centre #85"

    Saint Petersburg, 198260

  • SBIH "Samara Regional Clinical Hospital n.a. V.D. Seredavin"

    Samara, 443095

  • NSHI "Departmental Hospital at Smolensk station OJSC "Russian Railways"

    Smolensk, 214025

  • SAHI YR Clinical Hospital of Emergency Medical Care n.a. N.V. Soloviev

    Yaroslavl, 150003

  • State Budgetary Institution of Healthcare of Yaroslavl Region "Regional Clinical Hospital"

    Yaroslavl, 150062

Other trials in Russia

Poland7 sites
  • Zdrowie OSTEO-MEDIC s.c. L i A. Racewicz, A i J. Supronik

    Bialystok, 15-351

  • ClinicMed Daniluk, Nowak. Sp. j.

    Bialystok, 15-879

  • Nzoz Bif - Med

    Bytom, 41-902

  • Centrum Medyczne Pratia Krakow

    Krakow, 30-002

  • Malopolskie Centrum Medyczne S.C.

    Krakow, 30-510

  • NZOZ Lecznica MAK-MED. S.C.

    Nadarzyn, 05-830

  • MTZ Clinical Research Sp. z o.o.

    Warsaw, 02-106

Other trials in Poland

South Korea7 sites
  • Clinical Trial Pharmacy, KyungHee University Hospital

    Seoul, 02447

  • KyungHee University Hospital

    Seoul, 02447

  • CTC Pharmacy, Seoul National University Hospital

    Seoul, 03080

  • Seoul National University Hospital

    Seoul, 03080

  • Konkuk University Medical Center

    Seoul, 05030

  • Clinical Trial Pharmacy, The Catholic University of Korea, Seoul St. Mary's Hospital

    Seoul, 06591

  • The Catholic University of Korea Seoul, St. Mary's Hospital

    Seoul, 06591

Other trials in South Korea

Bulgaria6 sites
  • University Multiprofile Hospital for Active Treatment Dr. G. Stranski EAD

    Pleven, 5800

  • Multiprofile Hospital for Active Treatment - Plovdiv AD, Rheumatology Department

    Plovdiv, 4000

  • Multiprofile Hospital for Active Treatment Trimontium OOD

    Plovdiv, 4000

  • University Multiprofile Hospital for Active Treatment - Kaspela EOOD

    Plovdiv, 4001

  • National Multiprofile Transport Hospital Tsar Boris III

    Sofia, 1233

  • Medical Centre Synexus Sofia EOOD

    Sofia, 1784

Other trials in Bulgaria

Slovakia5 sites
  • AAGS s.r.o.

    Dunajská Streda, 929 01

  • MEDMAN s.r.o.

    Martin, 03601

  • REUMACENTRUM s.r.o.

    Partizánske, 958 01

  • MUDr. Zuzana Cizmarikova, s.r.o.

    Poprad, 05801

  • Reumex s.r.o

    Rimavská Sobota, 979 01

Other trials in Slovakia

Australia4 sites
  • Genesis Research Services Pty Ltd

    Broadmeadow, New South Wales, 2292

  • Optimus Clinical Research Pty Ltd

    Kogarah, New South Wales, 2217

  • Rheumatology Research Unit

    Maroochydore, Queensland, 4558

  • Emeritus Research

    Melbourne, Victoria, 3124

Other trials in Australia

Hungary4 sites
  • DRC Gyogyszervizsgalo Kozpont Kft.

    Balatonfüred, 8230

  • Revita Rendelo

    Budapest, 1027

  • Qualiclinic Kft.

    Budapest, 1036

  • CRU Hungary Kft.

    Miskolc, 3529

Other trials in Hungary

Spain3 sites
  • Hospital Universitario de Cruces

    Barakaldo, Vizcaya, 48903

  • Complejo Hospitalario Universitario de Santiago

    Santiago de Compostela, A Coruna, 15706

  • Hospital Infanta Luisa

    Seville, 41010

Other trials in Spain

Belgium2 sites
  • ReumaClinic

    Genk, 3600

  • AZ Delta

    Roeselare, 8800

Other trials in Belgium

Mexico2 sites
  • Morales Vargas Centro de Investigacion SC (Consultorio Anexo)

    León, Guanajuato, 37000

  • Centro de Investigacion y Tratamiento Reumatologico SC Consultorio Medico de Reumatologia (CINTRE)

    Mexico City, Mexico City, 11850

Other trials in Mexico

Philippines2 sites
  • Mary Mediatrix Medical Center

    Lipa City, Batangas, 4217

  • Far Eastern University - Nicanor Reyes Medical Foundation, Marian Medical Arts Bldg

    Quezon City, National Capital Region, 1118

Other trials in Philippines

Germany1 site
  • Hamburger Rheuma Forschungszentrum I

    Hamburg, 22391

Other trials in Germany

South Africa1 site
  • St. Augustine's Hospital

    Durban, KwaZulu-Natal, 4001

Other trials in South Africa

About this study

Official title: A PHASE 3B/4 RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF METHOTREXATE (MTX) WITHDRAWAL IN SUBJECTS WITH RHEUMATOID ARTHRITIS (RA) TREATED WITH TOFACITINIB 11MG MODIFIED RELEASE (MR) FORMULATION

This study is designed to evaluate the efficacy and safety of tofacitinib modified release formulation (11mg QD) versus tofacitinib modified release formulation plus continued methotrexate treatment in subjects with moderate to severe rheumatoid arthritis who are insufficiently responding to their stable dose of methotrexate treatment.

Being tested
CP-690,550, Methotrexate, Placebo
Keywords
Rheumatoid Arthritis, Tofacitinib, CP-690,550, Xeljanz, methotrexate withdrawal, withdrawal study
Medical subject headings
Arthritis, Rheumatoid

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CP-690,550Drug

    Also called tofacitinib

    During the open-label run-in phase (Day 1 to Week 24), all subjects will receive one tablet open-label tofacitinib MR 11mg orally QD and open-label methotrexate capsule(s) orally every week at prior stabilized dose.

    During the double-blind phase, subjects who are randomized to the treatment arm will receive the same dosage of tofacitinib and methotrexate as describe above.

  • MethotrexateDrug

    During the open-label run-in phase (Day 1 to Week 24), all subjects will receive one tablet open-label tofacitinib MR 11mg orally QD and open-label methotrexate capsule(s) orally every week at prior stabilized dose.

    During the double-blind phase, subjects who are randomized to the treatment arm will receive the same dosage of tofacitinib and methotrexate as describe above.

  • PlaceboDrug

    During the double-blind phase, subjects who are randomized to the comparison arm will receive 11mg QD tofacitinib and the placebo capsules matching for methotrexate.

Study groups in NCT02831855
Study groupRoleWhat they receive
CP-690,550 and methotrexateExperimentalOpen-label tofacitinib tablet and blinded methotrexate capsule
Receives: Drug: CP-690,550; Drug: Methotrexate
CP-690,550 and placeboPlacebo comparatoropen-label tofacitinib tablet and blinded matching placebo for methotrexate capsule
Receives: Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Double Blind Phase: Change From Randomization in Disease Activity Score in 28 Joints Using 4 Variables (DAS28-4) (Erythrocyte Sedimentation Rate [ESR]) at Week 48

    DAS28 is a measure of disease activity in participants with rheumatoid arthritis. DAS28-4 (ESR) was calculated from swollen joint count (SJC) and tender/painful joint count (TJC) using 28 joints count, ESR (millimeters per hour [mm/hr]) and participant global assessment of arthritis (PtGA) on a 100 millimeter (mm) visual analog scale (VAS: scores ranging from 0 mm [very well] to 100 mm [worst], higher scores indicate worse health condition). Total DAS28-4 (ESR) score range: 0 (none) to 9.4 (extreme disease activity), higher score indicated more disease activity. DAS28-4 (ESR) less than or equal to (<=) 3.2 implied low disease activity and greater than (>) 3.2 to <=5.1 implied moderate disease activity, >5.1 implied high disease activity, and DAS28-4 (ESR) less than (<) 2.6 implied remission. DAS28-4 (ESR) = 0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.70*In(ESR in mm/hour) + 0.014*PtGA in mm; ln = natural logarithm, sqrt = square root of.

    Measured: Randomization (last non-missing measurement on or prior to the first dosing date in DB phase at Week 24), Week 48

Secondary outcomes (23)
  1. Double Blind Phase: Change From Randomization in DAS28-4 ESR at Week 36

    DAS28 is a measure of disease activity in participants with rheumatoid arthritis. DAS28-4 (ESR) was calculated from SJC and TJC using 28 joints count, ESR (mm/hr) and PtGA on a 100 millimeter (mm) VAS (VAS: scores ranging from 0 mm [very well] to 100 mm [worst], higher scores indicate worse health condition). Total DAS28-4 (ESR) score range: 0 (none) to 9.4 (extreme disease activity), higher score indicated more disease activity. DAS28-4 (ESR) less than or equal to (<=) 3.2 implied low disease activity and greater than (>) 3.2 to <=5.1 implied moderate disease activity, >5.1 implied high disease activity, and DAS28-4 (ESR) less than (<) 2.6 implied remission. DAS28-4 (ESR) = 0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.70*In(ESR in mm/hour) + 0.014*PtGA in mm; ln = natural logarithm, sqrt = square root of.

    Measured: Randomization (last non-missing measurement on or prior to the first dosing date in DB phase at Week 24), Week 36

  2. Double Blind Phase: Change From Randomization in DAS28-4 (C-reactive Protein [CRP]) at Weeks 36 and 48

    DAS28 is a measure of disease activity in participants with rheumatoid arthritis. DAS28-4 (CRP) was calculated from SJC and TJC using 28 joints count, CRP (milligrams per liter [mg/L]) and PtGA on a 100 mm VAS (VAS: scores ranging from 0 mm [very well] to 100 mm [worst], higher scores indicate worse health condition). Total DAS28-4 (CRP) score range: 0 (none) to 9.4 (extreme disease activity), higher score indicated more disease activity. DAS28-4 (CRP) <= 3.2 implied low disease activity and > 3.2 to <=5.1 implied moderate disease activity, >5.1 implied high disease activity, and DAS28-4 (CRP) < 2.6 implied remission. DAS28-4 (CRP) = 0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.36*ln(CRP in mg/L +1) + 0.014*PtGA in mm+ 0.96; ln = natural logarithm, sqrt = square root of.

    Measured: Randomization (last non-missing measurement on or prior to the first dosing date in DB phase at Week 24), Weeks 36 and 48

  3. Double Blind Phase: Change From Randomization in Clinical Disease Activity Index (CDAI) at Weeks 36 and 48

    CDAI was calculated from tender and swollen joints using 28 joint count, PtGA and physician global assessment of arthritis (PhyGA). PtGA and PhyGA both were assessed on 0-10 centimeter (cm) VAS scale (VAS: scores ranging from 0 cm [very well] to 10 cm [worst]), where higher scores indicated greater affliction due to disease activity). CDAI total score ranged from 0 to 76, where higher scores indicated higher disease activity. CDAI score of <=10 indicated low disease activity and a score of <= 2.8 indicated remission. CDAI = (28TJC) + (28SJC) + (PhyGA in cm) + (PtGA in cm).

    Measured: Randomization (last non-missing measurement on or prior to the first dosing date in DB phase at Week 24), Weeks 36 and 48

  4. Double Blind Phase: Change From Randomization in Simplified Disease Activity Index (SDAI) at Weeks 36 and 48

    SDAI was calculated from tender and swollen joints using 28 joint count, PtGA, PhyGA and CRP (in mg/dL). PtGA and PhyGA both were assessed on 0-10 cm VAS scale (VAS: scores ranging from 0 cm [very well] to 10 cm [worst]), where higher scores indicated greater affliction due to disease activity). SDAI total score ranged from 0 to 86, where higher scores indicated higher disease activity. SDAI score of <=11 indicates low disease activity and a score of <=3.3 indicates remission. SDAI = (28TJC) + (28SJC) + (PhyGA in cm) + (PtGA in cm) + (CRP in mg/dL).

    Measured: Randomization (last non-missing measurement on or prior to the first dosing date in DB phase at Week 24), Weeks 36 and 48

  5. Double Blind Phase: Percentage of Participants With Low Disease Activity (LDA) Assessed by DAS28-4 (ESR) Less Than or Equal to (<=) 3.2 at Weeks 36 and 48

    DAS28 is a measure of disease activity in participants with rheumatoid arthritis. DAS28-4 (ESR) was calculated from SJC and TJC using 28 joints count, ESR (mm/hr) and PtGA on a 100 mm VAS (VAS: scores ranging from 0 mm [very well] to 100 mm [worst], higher scores indicated worse health condition). Total DAS28-4 (ESR) score range: 0 (none) to 9.4 (extreme disease activity), higher score indicated more disease activity. DAS28-4 (ESR) <=3.2 implied low disease activity and >3.2 to <=5.1 implied moderate disease activity, >5.1 implied high disease activity, and DAS28-4 (ESR) <2.6 implied remission. DAS28-4 (ESR) = 0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.70*In(ESR in mm/hour) + 0.014*PtGA in mm; ln = natural logarithm, sqrt = square root of.

    Measured: Weeks 36 and 48

  6. Double Blind Phase: Percentage of Participants With LDA Assessed by DAS28-4 (CRP) <=3.2 at Weeks 36 and 48

    DAS28 is a measure of disease activity in participants with rheumatoid arthritis. DAS28-4 (CRP) was calculated from SJC and TJC using 28 joints count, CRP (mg/L) and PtGA on a 100 mm VAS (VAS: scores ranging from 0 mm [very well] to 100 mm [worst], higher scores indicate worse health condition). Total DAS28-4 (CRP) score range: 0 (none) to 9.4 (extreme disease activity), higher score indicated more disease activity. DAS28-4 (CRP) <=3.2 implied low disease activity and >3.2 to <=5.1 implied moderate disease activity, >5.1 implied high disease activity, and DAS28-4 (CRP) <2.6 implied remission. DAS28-4 (CRP) = 0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.36*ln(CRP in mg/L +1) + 0.014*PtGA in mm+ 0.96; ln = natural logarithm, sqrt = square root of.

    Measured: Weeks 36 and 48

  7. Double Blind Phase: Percentage of Participants With LDA Assessed by CDAI <=10 at Weeks 36 and 48

    CDAI was calculated from tender and swollen joints using 28 joint count, PtGA and PhyGA. PtGA and PhyGA both were assessed on 0-10 cm VAS scale (VAS: scores ranging from 0 cm [very well] to 10 cm [worst]), where higher scores indicated greater affliction due to disease activity). CDAI total score ranged from 0 to 76, where higher scores indicated higher disease activity. CDAI score of <=10 indicated low disease activity and a score of <= 2.8 indicated remission. Percentage of participants with CDAI <=10 were reported. CDAI = (28TJC) + (28SJC) + (PhyGA in cm) + (PtGA in cm).

    Measured: Weeks 36 and 48

  8. Double Blind Phase: Percentage of Participants With LDA Assessed by SDAI <=11 at Weeks 36 and 48

    SDAI was calculated from tender and swollen joints using 28 joint count, PtGA, PhyGA and CRP (in mg/dL). PtGA and PhyGA both were assessed on 0-10 cm VAS scale (VAS: scores ranging from 0 cm [very well] to 10 cm [worst]), where higher scores indicated greater affliction due to disease activity). SDAI total score ranged from 0 to 86, where higher scores indicated higher disease activity. SDAI score of <=11 indicated low disease activity and a score of <=3.3 indicated remission. SDAI = (28TJC) + (28SJC) + (PhyGA in cm) + (PtGA in cm) + (CRP in mg/dL).

    Measured: Weeks 36 and 48

  9. Double Blind Phase: Percentage of Participants With Remission Assessed by American College of Rheumatology-European League Against Rheumatism (ACR-EULAR) Boolean at Weeks 36 and 48

    ACR-EULAR Boolean remission was when a participant satisfied all of the following: tender joint count, swollen joint count (both based on a 28-joint assessment), CRP (in mg/dL), and PtGA (VAS: 0 cm [very well] to 10 cm [worst], higher scores indicated worse health condition) and all scores were <=1.

    Measured: Weeks 36 and 48

  10. Double Blind Phase: Percentage of Participants With Remission Assessed by DAS28-4 (ESR) Less Than [<] 2.6 at Weeks 36 and 48

    DAS28 is a measure of disease activity in participants with rheumatoid arthritis. DAS28-4 (ESR) was calculated from SJC and TJC using 28 joints count, ESR (mm/hr) and PtGA on a 100 mm VAS (VAS: scores ranging from 0 mm [very well] to 100 mm [worst], higher scores indicate worse health condition). Total DAS28-4 (ESR) score range: 0 (none) to 9.4 (extreme disease activity), higher score indicated more disease activity. DAS28-4 (ESR) <= 3.2 implied low disease activity and >3.2 to <=5.1 implied moderate disease activity, >5.1 implied high disease activity, and DAS28-4 (ESR) <2.6 implied remission. DAS28-4 (ESR) = 0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.70*In(ESR in mm/hour) + 0.014*PtGA in mm. Percentage of participants with DAS remission (DAS28-4-ESR<2.6) were reported in this outcome measure.

    Measured: Weeks 36 and 48

  11. Double Blind Phase: Percentage of Participants With Remission Assessed by DAS28-4 (CRP) <2.6 at Weeks 36 and 48

    DAS28 is a measure of disease activity in participants with rheumatoid arthritis. DAS28-4 (CRP) was calculated from SJC and TJC using 28 joints count, CRP (mg/L) and PtGA on a 100 mm VAS (VAS: scores ranging from 0 mm [very well] to 100 mm [worst], higher scores indicate worse health condition). Total DAS28-4 (CRP) score range: 0 (none) to 9.4 (extreme disease activity), higher score indicated more disease activity. DAS28-4 (CRP) <=3.2 implied low disease activity and >3.2 to <=5.1 implied moderate disease activity, >5.1 implied high disease activity, and DAS28-4 (CRP) <2.6 implied remission. DAS28-4 (CRP) = 0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.36*ln(CRP in mg/l +1) + 0.014*PtGA in mm+ 0.96. Percentage of participants with DAS remission (DAS28-4-CRP<2.6) were reported in this outcome measure.

    Measured: Weeks 36 and 48

  12. Double Blind Phase: Percentage of Participants With Remission Assessed by CDAI <=2.8 at Weeks 36 and 48

    CDAI was calculated from tender and swollen joints using 28 joint count, PtGA and PhyGA. PtGA and PhyGA both were assessed on 0-10 cm VAS scale (VAS: scores ranging from 0 cm [very well] to 10 cm [worst]), where higher scores indicated greater affliction due to disease activity). CDAI total score ranged from 0 to 76, where higher scores indicated higher disease activity. CDAI score of <=10 indicated low disease activity and a score of <= 2.8 indicated remission. CDAI = (28TJC) + (28SJC) + (PhyGA in cm) + (PtGA in cm).

    Measured: Weeks 36 and 48

  13. Double Blind Phase: Percentage of Participants With Remission Assessed by SDAI <=3.3 at Weeks 36 and 48

    SDAI was calculated from tender and swollen joints using 28 joint count, PtGA, PhyGA and CRP (in mg/dL). PtGA and PhyGA both were assessed on 0-10 cm VAS scale (VAS: scores ranging from 0 cm [very well] to 10 cm [worst]), where higher scores indicated greater affliction due to disease activity). SDAI total score ranged from 0 to 86, where higher scores indicated higher disease activity. SDAI score of <=11 indicates low disease activity and a score of <=3.3 indicates remission. SDAI = (28TJC) + (28SJC) + (PhyGA in cm) + (PtGA in cm) + (CRP in mg/dL).

    Measured: Weeks 36 and 48

  14. Double Blind Phase: Percentage of Participants Achieving an American College of Rheumatology 20 Percent (%) (ACR20) Response at Weeks 36 and 48

    Participants with 20% improvement in tender and swollen joint counts and 20% improvement in at least 3 of the 5 measures: PtGA, PhyGA, participant's assessment of arthritis pain, Health Assessment Questionnaire-Disability Index (HAQ-DI) and CRP. PtGA: participant assessed health on VAS, 0 mm (very well) to 100 mm (worst health condition), higher scores = worse condition. PhyGA: physician judged participants' pain on VAS, 0 (no pain) to 100 mm (extreme pain), higher scores = more pain. Participant's assessment of arthritis pain: participant assessed pain on VAS, 0 mm (no pain) to 100 mm (most severe pain), higher score = more pain. HAQ-DI: functional disability evaluation, score: 0 (no difficulty) to 3 (extreme difficulty), higher score implied more disability. The improvement was relative to baseline (Day 1).

    Measured: Baseline (Day 1), Weeks 36 and 48

  15. Double Blind Phase: Percentage of Participants Achieving an American College of Rheumatology 50% (ACR50) Response at Weeks 36 and 48

    Participants with 50% improvement in tender and swollen joint counts and 50% improvement in at least 3 of the 5 measures: PtGA, PhyGA, participant's assessment of arthritis pain, HAQ-DI and CRP. PtGA: participant assessed health on VAS, 0 mm (very well) to 100 mm (worst health condition), higher scores = worse condition. PhyGA: physician judged participants' pain on VAS, 0 (no pain) to 100 mm (extreme pain), higher scores = more pain. Participant's assessment of arthritis pain: participant assessed pain on VAS, 0 mm (no pain) to 100 mm (most severe pain), higher score = more pain. HAQ-DI: functional disability evaluation, score: 0 (no difficulty) to 3 (extreme difficulty), higher score implied more disability. The improvement was relative to baseline (Day 1).

    Measured: Baseline (Day 1), Weeks 36 and 48

  16. Double Blind Phase: Percentage of Participants Achieving an American College of Rheumatology 70% (ACR70) Response at Weeks 36 and 48

    Participants with 70% improvement in tender and swollen joint counts and 70% improvement in at least 3 of the 5 measures: PtGA, PhyGA, participant's assessment of arthritis pain, HAQ-DI and CRP. PtGA: participant assessed health on VAS, 0 mm (very well) to 100 mm (worst health condition), higher scores = worse condition. PhyGA: physician judged participants' pain on VAS, 0 (no pain) to 100 mm (extreme pain), higher scores = more pain. Participant's assessment of arthritis pain: participant assessed pain on VAS, 0 mm (no pain) to 100 mm (most severe pain), higher score = more pain. HAQ-DI: functional disability evaluation, score: 0 (no difficulty) to 3 (extreme difficulty), higher score implied more disability. The improvement was relative to baseline (Day 1).

    Measured: Baseline (Day 1), Weeks 36 and 48

  17. Double Blind Phase: Change From Randomization in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Weeks 36 and 48

    HAQ-DI assesses the degree of difficulty a participant has experienced during the past week in 8 domains of daily living activities: dressing/grooming; arising; eating; walking; reach; grip; hygiene; and other activities.. There were total of 30 items distributed in these 8 domains. Each item was scored on a 4-point scale from 0 to 3: 0= no difficulty; 1= some difficulty; 2= much difficulty; 3= unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0 (least difficulty) and 3 (extreme difficulty), where higher scores indicate more difficulty while performing daily living activities.

    Measured: Randomization (last non-missing measurement on or prior to the first dosing date in DB phase at Week 24), Weeks 36 and 48

  18. Double Blind Phase: Change From Randomization in the Short Form 36 (SF-36) Health Survey 8 Domain Scores at Weeks 36 and 48

    SF-36 is a participant reported standardized survey designed to assess generic health related quality of life. It consisted of 36 items evaluating 8 aspects of functional health and well-being: physical functioning, role physical, bodily pain, social functioning, mental health, role emotional, vitality, and general health perception. The score range for each of the 8 health aspects was from 0 (poor health) to 100 (better health), higher scores indicating good health condition. Scores of 8 health aspects were summarized to derive the 2 component scores (physical component scores [PCS], mental component scores [MCS]) ranging from 0 (worst) to 100 (best), where higher PCS/MCS indicated good health condition.

    Measured: Randomization (last non-missing measurement on or prior to the first dosing date in DB phase at Week 24), Weeks 36 and 48

  19. Double Blind Phase: Change From Randomization in the SF-36 Health Survey Component Scores at Weeks 36 and 48

    SF-36 is a participant reported standardized survey designed to assess generic health related quality of life. It consisted of 36 items evaluating 8 aspects of functional health and well-being: physical functioning, role physical, bodily pain, social functioning, mental health, role emotional, vitality, and general health perception. The score range for each of the 8 health aspects was from 0 (poor health) to 100 (better health), higher scores indicating good health condition. Scores of 8 health aspects were summarized aggregated to derive the two 2 component scores PCS and MCS ranging from 0 (worst) to 100 (best), where higher PCS/MCS indicated good health condition.

    Measured: Randomization (last non-missing measurement on or prior to the first dosing date in DB phase at Week 24), Weeks 36 and 48

  20. Double Blind Phase: Change From Randomization in the Work Productivity and Activity Impairment (WPAI) Scores at Week 36 and 48

    WPAI is 6-question participant rated questionnaire to determine the impact of rheumatoid arthritis and yields 4 types of outcomes: absenteeism (work time missed), presenteeism (impairment while working), work productivity loss (overall work impairment), and daily activity impairment (activity impairment) for a period of 7 days prior to a visit. These 4 outcomes are expressed as an impairment percentage (range from 0 to 100), with higher numbers indicating greater impairment and less productivity.

    Measured: Randomization (last non-missing measurement on or prior to the first dosing date in DB phase at Week 24), Week 36 and 48

  21. Double Blind Phase: Change From Randomization in the European Quality of Life - 5 Dimensions Questionnaire (EQ-5D) Scores at Weeks 36 and 48

    EQ-5D was a participant completed instrument designed to assess impact on quality of life in terms of a single utility score in 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. 3 possible answers for mobility: 1=no problem in walking, 2=moderate problems in walking, 3= confined to bed; self-care: 1=no problem, 2=moderate problems, 3= unable to wash/dress; usual activities: 1=no problem, 2=moderate problems, 3= unable to do usual activities; pain and discomfort: 1=no pain or discomfort, 2=moderate pain or discomfort, 3= extreme pain or discomfort; anxiety and depression: 1=not anxious or depressed, 2=moderately anxious or depressed, 3= extremely anxious or depressed. The 5-dimensional systems are converted into a single index utility score between 0 and 1, where higher score indicated a better health state.

    Measured: Randomization (last non-missing measurement on or prior to the first dosing date in DB phase at Week 24), Weeks 36 and 48

  22. Double Blind Phase: Change From Randomization in the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale Scores at Weeks 36 and 48

    The FACIT-Fatigue scale was a participant completed questionnaire consisted of 13 items that assessed fatigue. Each item was scored on a scale of 0 (maximum fatigue) to 4 (no fatigue), higher scores indicate less fatigue. Total FACIT-fatigue score was obtained by addition of scores from 13 items, giving a possible overall range from 0 (maximum fatigue) to 52 (no fatigue). Higher FACIT-fatigue scores indicated lower level of fatigue, better participant status.

    Measured: Randomization (last non-missing measurement on or prior to the first dosing date in DB phase at Week 24), Weeks 36 and 48

  23. Double Blind Phase: Percentage of Participants Achieving an Improvement of at Least 0.22 Units in HAQ-DI at Weeks 36 and 48

    HAQ-DI assesses the degree of difficulty a participant has experienced during the past week in 8 domains of daily living activities: dressing/grooming; arising; eating; walking; reach; grip; hygiene; and other activities.. There were total of 30 items distributed in these 8 domains. Each item was scored on a 4-point scale from 0 to 3: 0= no difficulty; 1= some difficulty; 2= much difficulty; 3= unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0 (least difficulty) and 3 (extreme difficulty), where higher scores indicate more difficulty while performing daily living activities. Percentage of participants with an improvement of at least 0.22 units in HAQ scores from baseline (Day 1) to Weeks 36 and 48 were reported in this outcome measure.

    Measured: Baseline (Day 1), Weeks 36 and 48

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Jul 2016 (estimated)
  2. Study start1 Sep 2016
  3. Primary completion19 Nov 2018
  4. Study completion17 Dec 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
694 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02831855
Sponsor's protocol ID
A3921192
Other IDs
2016-001825-15, 2016
Status last verified
Nov 2019
First submitted
11 Jul 2016
Last updated
4 Dec 2019
Data monitoring committee
Yes
Individual data sharing
Yes: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.

Publications

  • Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, Chan KW, Ciceri P, Davis MI, Edeen PT, Faraoni R, Floyd M, Hunt JP, Lockhart DJ, Milanov ZV, Morrison MJ, Pallares G, Patel HK, Pritchard S, Wodicka LM, Zarrinkar PP. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 2008 Jan;26(1):127-32. doi: 10.1038/nbt1358.

    PubMed 18183025
  • Meyer DM, Jesson MI, Li X, Elrick MM, Funckes-Shippy CL, Warner JD, Gross CJ, Dowty ME, Ramaiah SK, Hirsch JL, Saabye MJ, Barks JL, Kishore N, Morris DL. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm (Lond). 2010 Aug 11;7:41. doi: 10.1186/1476-9255-7-41.

    PubMed 20701804
  • Murray PJ. The JAK-STAT signaling pathway: input and output integration. J Immunol. 2007 Mar 1;178(5):2623-9. doi: 10.4049/jimmunol.178.5.2623.

    PubMed 17312100
  • O'Sullivan LA, Liongue C, Lewis RS, Stephenson SE, Ward AC. Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease. Mol Immunol. 2007 Apr;44(10):2497-506. doi: 10.1016/j.molimm.2006.11.025. Epub 2007 Jan 17.

    PubMed 17208301
  • Fleischmann R, Cutolo M, Genovese MC, Lee EB, Kanik KS, Sadis S, Connell CA, Gruben D, Krishnaswami S, Wallenstein G, Wilkinson BE, Zwillich SH. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum. 2012 Mar;64(3):617-29. doi: 10.1002/art.33383.

    PubMed 21952978
  • Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, Gruben D, Wallenstein GV, Zwillich SH, Kanik KS; ORAL Solo Investigators. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012 Aug 9;367(6):495-507. doi: 10.1056/NEJMoa1109071.

    PubMed 22873530
  • Kremer JM, Cohen S, Wilkinson BE, Connell CA, French JL, Gomez-Reino J, Gruben D, Kanik KS, Krishnaswami S, Pascual-Ramos V, Wallenstein G, Zwillich SH. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum. 2012 Apr;64(4):970-81. doi: 10.1002/art.33419. Epub 2011 Oct 17.

    PubMed 22006202
  • Kremer J, Li ZG, Hall S, Fleischmann R, Genovese M, Martin-Mola E, Isaacs JD, Gruben D, Wallenstein G, Krishnaswami S, Zwillich SH, Koncz T, Riese R, Bradley J. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2013 Aug 20;159(4):253-61. doi: 10.7326/0003-4819-159-4-201308200-00006.

    PubMed 24026258
  • Burmester GR, Benda B, Gruben D, Bradley J, Mebus C. Tofacitinib for rheumatoid arthritis - Authors' reply. Lancet. 2013 May 25;381(9880):1812-3. doi: 10.1016/S0140-6736(13)61115-0. No abstract available.

    PubMed 23706795
  • van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, Garcia Meijide JA, Wagner S, Forejtova S, Zwillich SH, Gruben D, Koncz T, Wallenstein GV, Krishnaswami S, Bradley JD, Wilkinson B; ORAL Standard Investigators. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012 Aug 9;367(6):508-19. doi: 10.1056/NEJMoa1112072.

    PubMed 22873531
  • Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, Aletaha D, Allaart CF, Bathon J, Bombardieri S, Brooks P, Brown A, Matucci-Cerinic M, Choi H, Combe B, de Wit M, Dougados M, Emery P, Furst D, Gomez-Reino J, Hawker G, Keystone E, Khanna D, Kirwan J, Kvien TK, Landewe R, Listing J, Michaud K, Martin-Mola E, Montie P, Pincus T, Richards P, Siegel JN, Simon LS, Sokka T, Strand V, Tugwell P, Tyndall A, van der Heijde D, Verstappen S, White B, Wolfe F, Zink A, Boers M; American College of Rheumatology; European League Against Rheumatism. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011 Mar;63(3):573-86. doi: 10.1002/art.30129.

    PubMed 21294106
  • Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol. 1982 Sep-Oct;9(5):789-93. No abstract available.

    PubMed 7175852
  • Ware JE KM, Dewey JE. . How to score Version 2 of the SF 36 Health Survey (Standard & Acute forms). In: How to score Version 2 of the SF 36 Health Survey (Standard & Acute forms). Lincoln, Rhode Island: QualityMetric, Incorporated. 2000.

  • Hurst NP, Kind P, Ruta D, Hunter M, Stubbings A. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br J Rheumatol. 1997 May;36(5):551-9. doi: 10.1093/rheumatology/36.5.551.

    PubMed 9189057
  • Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993 Nov;4(5):353-65. doi: 10.2165/00019053-199304050-00006.

    PubMed 10146874

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing CP-690,550 and Methotrexate in people with Rheumatoid Arthritis, run by Pfizer at 136 sites in 16 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 4 Dec 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 136 sites in United States, Czechia, United Kingdom, Russia, Poland and 11 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 4 Dec 2019). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Double Blind Phase: Change From Randomization in Disease Activity Score in 28 Joints Using 4 Variables (DAS28-4) (Erythrocyte Sedimentation Rate [ESR]) at Week 48 (time frame: Randomization (last non-missing measurement on or prior to the first dosing date in DB phase at Week 24), Week 48). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02831855, which also lists 25 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Dec 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in